Dr. Clay Siegall, the founder and Chief Executive Officer of Seattle Genetics, is the proponent of targeted therapies in cancer, and he leads the team at his research firm to focus on result-oriented treatment. Seattle Genetics is a healthcare research firm which focuses on developing antibody-based targeted therapies to treat cancer. Dr. Clay Siegall is a critic of old style systemic chemotherapies and thinks that it is the time to put those types of treatments into the dustbin. He recalls that during his younger days, one of his relatives was treated for cancer, and the patient was going through brutal treatment regime. The experience led Dr. Siegall to focus his efforts to advance and simplify the treatment procedure that drives better results than almost killing them.
Dr. Siegall said that while he was venturing his own research firm, it took a lot of struggles to make the institution profitable. Especially during the initial years, the operating capital depleted multiple times, and as he was a workaholic person, he put his efforts to the work along with his colleagues and waited for time to come. Dr. Siegall thankfully remembers the dynamic sales staff of the firm, who turned things positive with their broad backgrounds in biotech. Apart from the sales team, the research team came up with some innovative products promptly and ensured a sustained growth of the firm. Dr. Siegall has all praise for hard work and states that it is the primary characteristic that differentiates humans from animals.
Dr. Siegall co-founded the firm in 1998 and developed it on the visions of rigorous research and scientific innovation to substantially increase the survival rate on some of the deadly diseases. His focused approach to providing better treatment solutions for cancer and other chronic diseases made the firm becoming the leader in antibody-drug conjugates (ADCs) for cancer treatment.
He is on the board of directors of some biotechnology firms and organizations including Alder Biopharmaceuticals Inc., Mirna Therapeutics, Inc., and Ultragenyx Pharmaceutical. Dr. Siegall completed his B.S. in Zoology from University of Maryland and later did his Doctor of Philosophy (Ph.D.) in Genetics from The George Washington University.